CoChat

Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics

Open access
Humbert, M., De Blay, F., Garcia, G., Prud’homme, A., Leroyer, C., Magnan, A., Tunon‐de‐Lara, J.‐M., Pison, C., Aubier, M., Charpin, D., Vachier, I., Purohit, A., Gineste, P., Bader, T., Moussy, A., Hermine, O., Chanez, P. · 2009 · Allergy
Cited by 135

The DOI matches its Crossref record.

Abstract

Background: Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c‐kit) and platelet‐derived growth factor (PDGF) receptor, which are expressed on several cell types including mast cells and bronchial structural cells, respectively. We hypothesized that c‐kit and PDGF receptor inhibition may decrease bronchial inflammation and interfere with airway remodeling, which are crucial features of severe asthma. Objectives: The primary endpoint was the percent change from baseline in oral corticosteroids after 16 weeks of treatment. Change in asthma control (asthma control questionnaire), exacerbation rate, pulmonary function tests, rescue medication requirement and safety were secondary endpoints. Methods: A 16‐week randomized, dose‐ranging (3, 4.5, and 6 mg/kg/day), placebo‐controlled study was undertaken in 44 patients with severe corticosteroid‐dependent asthma who remained poorly controlled despite optimal asthma management. Results: At 16 weeks of treatment, a comparable reduction in oral corticosteroids was achieved with masitinib and placebo (median reduction of ­78% and ­57% in the masitinib and placebo arms, respectively). Despite this similar reduction, the Asthma Control Questionnaire score was significantly better in the masitinib arm as compared to placebo with a reduction by 0.99 unit at week 16 (P < 0.001) vs 0.43 unit in the placebo arm. Masitinib therapy was associated with more transient skin rash and edema. Conclusions: Masitinib, a c‐kit and PDGF‐receptor tyrosine kinase inhibitor, may represent an innovative avenue of treatment in corticosteroid‐dependent asthma. These preliminary results warrant further long‐term clinical studies in severe asthma (ClinicalTrials.gov Identifier: NCT00842270).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1398-9995.2009.02122.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 135

Metadata

Authors
Humbert, M., De Blay, F., Garcia, G., Prud’homme, A., Leroyer, C., Magnan, A., Tunon‐de‐Lara, J. ‐., Pison, C., Aubier, M., Charpin, D., Vachier, I., Purohit, A., Gineste, P., Bader, T., Moussy, A., Hermine, O., & Chanez, P.
Venue
Allergy
Publisher
Wiley
Published
2009-07-08
Volume
64
Issue
8
Pages
1194-1201
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W2171835158
Cited by
135
References
0
FWCI
7.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics. https://app.cochat.ai/papers/10.1111/j.1398-9995.2009.02122.x
The paper
Humbert, M., De Blay, F., Garcia, G., Prud’homme, A., Leroyer, C., Magnan, A., Tunon‐de‐Lara, J. ‐., Pison, C., Aubier, M., Charpin, D., Vachier, I., Purohit, A., Gineste, P., Bader, T., Moussy, A., Hermine, O., & Chanez, P. (2009). Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics. Allergy. https://doi.org/10.1111/j.1398-9995.2009.02122.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.